16th Nov 2026 09:02
(Sharecast News) - Drugmaker Astrazeneca said on Monday that its rare disease division Alexion had secured regulatory approvals for Klygefa (gefurulimab) in both the European Union and the United States for the treatment of adults with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody positive.
The approvals from the European Commission and the Food and Drug Administration mark an important milestone for the therapy, which Astrazeneca said was the first and only approved dual-binding nanobody C5 inhibitor in both markets. Klygefa was administered through a once-weekly subcutaneous injection via autoinjector, offering patients a self-administered treatment option.
Both approvals were supported by results from the pivotal PREVAIL Phase III trial, which met its primary endpoint by delivering a statistically significant improvement in Myasthenia Gravis activities of daily living scores compared with placebo. AstraZeneca said patients experienced clinically meaningful benefits as early as the first week of treatment, with improvements sustained through week 26 and, in the US filing, through one year.
Generalised myasthenia gravis is a rare autoimmune disease that causes muscle weakness and fatigue. AstraZeneca said Klygefa was generally well tolerated in clinical studies, with a safety profile consistent with previous C5 inhibitors.
The drug is already approved in a number of markets, including Japan, while regulatory submissions based on the PREVAIL data remain under review in China and other territories.
As of 0900 GMT, Astrazeneca shares were up 0.86% at 13,994p.
Reporting by Iain Gilbert at Sharecast.com
See latest RNS on Sharecast